Implantable cardioverter defibrillators (ICDs) are moderately cost-effective for preventing sudden cardiac death, report researchers in the April 15 issue of Circulation: Journal of the American Heart Association.
In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, the devices were shown to be superior to therapy with antiarrhythmic medications for reducing all causes of death in survivors of ventricular fibrillation, said Greg Larsen, MD, lead author and staff cardiologist at the Portland Veterans Affairs Medical Center in Oregon.
Mitka M. ICDs Are Cost-effective. JAMA. 2002;287(20):2645. doi:10.1001/jama.287.20.2645-JQU20005-3-1